View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Res Ther 2023; 2023;18;25(1):172 doi 10.1186/s13075-023-03128-1
The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.
Front Pharmacol. 2023; 8(14):1237234 doi 10.3389/fphar.2023.1237234
This meta-analysis by Wei, et al. found that JAKi therapy was not associated with a higher risk of MACE than treatment with adalimumab, abatacept, or placebo. However, a higher incidence of all-cause mortality was observed with tofacitinib treatment than with adalimumab treatment.
Rheumatology (Oxford) 2023;63(2):298–308 doi 10.1093/rheumatology/kead448
JAKis differ in structure, which affects their inhibitory concentration for different JAKs.
This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.
Pharmacology 2023;108(6):589–598 doi 10.1159/000527186
The results of a Bayesian network meta-analysis by Lee and Song showed that JAK inhibitors were more likely to achieve remission and LDA in DMARD-naive RA patients than MTX. However, there were no significant differences in remission rates nor LDA rates between the JAK inhibitors investigated.
Adv Ther. 2023;40(10):4493–4503 doi 10.1007/s12325-023-02619-6
This study by Bergman, et al. showed that RA patients are significantly more likely to adhere to upadacitinib within the first 12 months of prescription versus adalimumab, baricitinib, and tofacitinib. There was also a significantly lower risk of discontinuation for upadacitinib versus the other treatment prescriptions.
J Clin Rheumatol. 2023;29(5):223–229 doi: 10.1097/RHU.0000000000001973
Phase 2a study assessing the efficacy and safety of tildrakizumab in patients with active AS fails to meet the primary endpoint.
Lancet Reg Health Eur. 2023;33:100706 doi: 10.1016/j.lanepe.2023.100706
Comparing the alignment of European national recommendations for patients with PsA and axSpA with EULAR and ASAS-EULAR treatment recommendations found that only a minority of national treatment recommendations were completely aligned.
J Clin Med. 2023;12(15):5153 doi: 10.3390/jcm12155153
Findings from a retrospective electronic data-based study, assessing risk of overall and site-specific malignancies for AS patients in Israel, emphasize the importance of maintaining the routine observation of patients with AS to identify the early development of cancer.
J Rheumatol. 2023;50(8):1020–1028 doi: 10.3899/jrheum.221022
Three-year data from the ixekizumab (IXE) COAST programme provide additional evidence that patients with axSpA receiving IXE experience long-term safety, and sustained improvements in efficacy outcomes, at 3 years.
ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11589
Whole blood transcriptome profiling reveals differential gene expression in patients with active PsA from the DISCOVER-1 and DISCOVER-2 clinical studies in comparison with healthy controls.
